Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 66,200 shares, a decrease of 21.3% from the February 13th total of 84,100 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average trading volume of 122,100 shares, the days-to-cover ratio is currently 0.5 days.

Hookipa Pharma Stock Up 5.0 %

Hookipa Pharma stock traded up $0.06 during midday trading on Tuesday, hitting $1.25. 28,413 shares of the stock were exchanged, compared to its average volume of 74,494. The company has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.80. Hookipa Pharma has a 52 week low of $1.11 and a 52 week high of $10.50. The stock has a market capitalization of $15.07 million, a PE ratio of -0.34 and a beta of 0.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Gilead Sciences Inc. bought a new position in Hookipa Pharma during the 4th quarter worth approximately $3,771,000. Ikarian Capital LLC bought a new position in Hookipa Pharma during the 3rd quarter worth approximately $228,000. Squarepoint Ops LLC bought a new position in Hookipa Pharma during the 4th quarter worth approximately $104,000. Finally, Millennium Management LLC bought a new position in Hookipa Pharma during the 4th quarter worth approximately $31,000. Institutional investors own 63.88% of the company’s stock.

Analysts Set New Price Targets

HOOK has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Hookipa Pharma in a report on Friday, January 10th. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $48.00 to $2.00 in a research note on Friday, December 20th. Finally, JMP Securities reduced their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.